Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow.

  Autonomic nervous system responses during sedative infusions of dexmedetomidine.

  The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation.

  The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects

  Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms.

  Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. [Review]

  Transmitters involved in antinociception in the spinal cord.

  The effects of dexmedetomidine on neuromuscular blockade in human volunteers.

  Dexmedetomidine does not alter the sweating threshold, but comparably and linearly decreases the vasoconstriction and shivering thresholds.

  Comparison of dexmedetomidine and midazolam sedation and antagonism of dexmedetomidine with atipamezole.

  Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate.

  The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery.

  Effect of dexmedetomidine and midazolam on human performance and mood.

  Contribution of alpha(2) receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine.

  Dual alpha(2)-adrenergic agonist and alpha(1)-adrenergic antagonist actions of dexmedetomidine on human isolated endothelium-denuded gastroepiploic arteries.

  Effect of dexmedetomidine on propofol requirements in healthy subjects.

  The analgesic action of dexmedetomidine--a novel alpha 2-adrenoceptor agonist--in healthy volunteers.

    Back to Summaries List